Lonza recently marked the groundbreaking of its first large-scale commercial drug product manufacturing facility, based in Stein, Switzerland. The facility is being delivered through an investment of approximately $545 million, as part of Lonza’s long-term growth strategy to build capacity in areas of high customer demand. Building on Lonza’s experience in drug product development, formulation and clinical manufacturing, the new facility will enable the company to provide an end-to-end offeri...